J 2019

Comparison of fourteen rule-out strategies for acute myocardial infarction

WILDI, Karin, Jasper BOEDDINGHAUS, Thomas NESTELBERGER, Raphael TWERENBOLD, Patrick BADERTSCHER et. al.

Basic information

Original name

Comparison of fourteen rule-out strategies for acute myocardial infarction

Authors

WILDI, Karin (756 Switzerland), Jasper BOEDDINGHAUS (756 Switzerland), Thomas NESTELBERGER (756 Switzerland), Raphael TWERENBOLD (756 Switzerland), Patrick BADERTSCHER (756 Switzerland), Desiree WUSSLER (756 Switzerland), Maria Rubini GIMENEZ (756 Switzerland), Christian PUELACHER (756 Switzerland), Jeanne du Fay de LAVALLAZ (756 Switzerland), Sebastian DIETSCHE (756 Switzerland), Joan WALTER (756 Switzerland), Nikola KOZHUHAROV (756 Switzerland), Beata MORAWIEC (380 Italy), Oscar MIRO (380 Italy), Javier F. MARTIN-SANCHEZ (380 Italy), Sinthuri SUBRAMANIAM (380 Italy), Nicolas GEIGY (756 Switzerland), Dagmar I. KELLER (756 Switzerland), Tobias REICHLIN (756 Switzerland), Christian MUELLER (756 Switzerland, guarantor), Deborah MUELLER (756 Switzerland), Lorraine SAZGARY (756 Switzerland), Stella MARBOT (756 Switzerland), Zaid SABTI (756 Switzerland), Dayana FLORES (756 Switzerland), Kathrin MEISSNER (756 Switzerland), Caroline KULANGARA (756 Switzerland), Michael FREESE (756 Switzerland), Stefan OSSWALD (756 Switzerland), Claudia STELZIG (756 Switzerland), Roland BINGISSER (756 Switzerland), Beatriz LOPEZ (724 Spain), María M. AGUERO (724 Spain), Ewa NOWALANY-KOZIELSKA (616 Poland), Damian KAWECKI (616 Poland), Jiří PAŘENICA (203 Czech Republic, belonging to the institution), Eva GANOVSKÁ (703 Slovakia, belonging to the institution), Jens LOHRMANN (756 Switzerland), Andreas BUSER (756 Switzerland), Dayana FLORES (756 Switzerland), Karin GRIMM (756 Switzerland), Beate HARTMANN (756 Switzerland), Piotr MUZYK (616 Poland), Katharina RENTSCH (756 Switzerland) and Arnold von ECKARDSTEIN (756 Switzerland)

Edition

International Journal of Cardiology, Clare, Elsevier Ireland Ltd. 2019, 0167-5273

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.229

RIV identification code

RIV/00216224:14110/19:00109666

Organization unit

Faculty of Medicine

UT WoS

000461330100007

Keywords in English

Acute myocardial infarction; Diagnosis; Rule-out; High-sensitivity cardiac troponin T and I; Rule-out algorithm; Efficacy

Tags

Tags

International impact, Reviewed
Změněno: 16/5/2019 13:41, Soňa Böhmová

Abstract

V originále

Background: The clinical availability of high-sensitivity cardiac troponin (hs-cTn) has enabled the development of several innovative strategies for the rapid rule-out of acute myocardial infarction (AMI). Due to the lack of direct comparisons, selection of the best strategy for clinical practice is challenging. Methods: In a prospective international multicenter diagnostic study enrolling 3696 patients presenting with suspected AMI to the emergency department, we compared the safety and efficacy of 14 different hs-cTn-based strategies: hs-cTn concentrations below the limit of detection (LoD), dual-marker combining hs-cTn with copeptin, ESC 0 h/1 h-algorithm, 0 h/2 h-algorithm, 2 h-ADP-algorithm, NICE-algorithm, and ESC 0 h/3 h-algorithm, each using either hs-cTnT or hs-cTnI. The final diagnosis of AMI was adjudicated by two independent cardiologists using all available clinical information including cardiac imaging and serial hs-cTn concentrations. Results: AMI was the final diagnosis in 16% of patients. Using hs-cTnT, safety quantified by the negative predictive value (NPV) and sensitivity was very high (99.8-100% and 99.5-100%) and comparable for all strategies, except the dual-marker approach (NPV 98.7%, sensitivity 96.7%). Similarly, using hs-cTnI, safety quantified by the NPV and sensitivity was very high (99.7-100% and 98.9-100%) and comparable for all strategies, except the dual-marker approach (NPV 96.9%, sensitivity 90.4%) and the NICE-algorithm (NPV 99.1%, sensitivity 94.7%). Efficacy, quantified by the percentage of patients eligible for rule-out, differed markedly, and was lowest for LoD-algorithm (15.7-26.8%). Conclusion: All rapid rule-out algorithms, except the dual-marker strategy and the NICE-algorithm using hs-cTnI, favorably combine safety and efficacy, and can be considered for routine clinical practice. Clinical trial registration: NCT00470587, http://clinicaltrials.gov/show/NCT00470587. (c) 2018 Elsevier B.V. All rights reserved.